Table 1. Selected rodent and primate EAE (and EAU models) and their indications representing aspects of MS³⁷.

Strain	Antigen	Induction	Clinical course	Pathology
MOUSE-EAE/EAU
C57BL6 (H-2b)	Spinal cord homogenate	Active	Resistant
	MOG (aa 35–55)	Active, passive	Severe, chronic-progressive, non-remitting	CNS demyelination, acute inflammation, axonal damage
	IRBP (aa 1–20)	Active	Mild, acute disease	Ocular inflammation
		Passive	Severe disease
	PLP	Passive	Very mild, resistant
B10RIII	IRBP (aa 161–180)	Active	Severe	Ocular inflammation
		Passive	Severe
C3H.SW (H-2b)	MOG (aa 35–55)	Active	Severe, chronic non-remitting	Inflammation, demyelination
SJL (H-2s)	Spinal cord homogenate	Active	Relapsing-remitting, Progressive (SCH, MBP)	Demyelination, inflammation
	MBP	Active, passive	Relapsing-remitting	Demyelination, inflammation
	PLP	Active, passive	Relapsing-remitting	Demyelination, inflammation
	MOG (aa 92–106)	Active, passive	Severe acute	Inflammation and demyelination
	MAG (myelin-associated glycoprotein) (aa 97–112)
	MOBP (myelin-associated/oligodendrocyte basic protein) (aa 37–60)	Active	Non-relapsing	Inflammation
	CNPase (2′,3′-cyclic nucleotide 3′-phosphodiesterase)
	OSP (oligodendrocyte-specific glycoprotein)
(B6 x SJL) F1 (H-2b/s)	MOG	Active	Relapsing-remitting	Inflammation, demyelination
B10.S (H-2s)	CNS homogenate	Active	Resistant
	MOG	Active	Resistant
ASW (H-2s)	MOG (aa 92–106)	Active	Depending on Bordetella pertussis application: +secondary progressive (SP)-primary progressive (PP)	Acute inflammation, demyelination
Biozzi AB/L (H-2s)	Brain homogenate		Resistant
Biozzi AB/H (H-2dq1)	Spinal cord homogenate	Active	Relapsing-remitting	Inflammation, demyelination in relapse phase
	MBP (aa 12–26; 21–35)	Active	Native MBP: resistant,MBP 12–26 and MBP 21–35: mild acute	Inflammation
	MOG (aa 1–22; 43–57; 134–148)	Active	Chronic relapsing (MOG 1–22)	Inflammation, no demyelination
			Chronic acute (MOG 35–55)	Native MOG: demyelination
	PLP (aa 56–70)	Active	Chronic relapsing	Inflammation, demyelination
	Ab-crystallin (aa 1–16)	Active	Acute mild	Inflammation
	GFAP (glial fibrillary acidic protein)	Active	Acute severe	Inflammation
ABH (H-2Ag7)	MAG (aa 97–112)
	OSP
	CNPase
NOD/Lt (H-2g7)	rMOG, MOG (aa 35–55)	Active	CREAE	Demyelination with peptide
NOD congenic strain III (H-2g7)	MOG	Active	Resistant
BALB/c (H-2d)	Spinal cord homogenate	Active	Resistant
	MBP (aa 59–76)	Passive	aEAE resistant, tEAE: acute	Inflammation, demyelination
	PLP (aa 178–191)	Active	Relatively resistant, atypical EAE
B10.PL (H-2u)	MBP (aa Ac1–9)	Active, passive
PL/J (H-2u)	MBP (aa 89–169)	Active, passive	CREAE	Demyelination, acute inflammation
	MBP (aa 1–37)		CREAE and chronic persisting paralysis
	MOG (aa 35–55)	Active, passive	Relapsing-remitting	Demyelination, acute inflammation
	PLP (aa 43–64)	Active, passive	CREAE	Demyelination, acute inflammation
DBA/1 (H-2q)	Spinal cord homogenate	Active	Resistant
	MOG (aa 79–96)	Active	Acute	Inflammation, demyelination
SWR/J (H-2q)	Spinal cord homogenate	Active
	PLP	Active
C3/HEJ (H-2k)	PLP	Active	Atypical EAE	Inflammation
RAT-EAE/EAU
Lewis (RT1-l)	Spinal cord homogenate	Active	Acute	CNS inflammation
	MBP (aa 68–88)	Active and passive	Acute, relapses after cyclosporine	CNS inflammation
	PLP	Active and passive	Weak acute	CNS inflammation
	MOG (aa 35–55)	Active and passive	Weak acute, after native MOG chronic progressive	CNS inflammation, demyelination with native MOG
	S100β (aa 76–91)	Passive	Weak acute	CNS inflammation
	GFAP	Passive	Weak acute	CNS inflammation
	IRBP (aa 177–1091)	Active	Acute, severe	Ocular inflammation
		Passive	Chronic, severe
	S-antigen	Active	Acute, modest	Ocular inflammation
Dark Agouti (DA) (RT1-av1)	Spinal cord homogenate	Active in incomplete FA	CREAE	CNS inflammation and demyelination
	MBP (aa 62–75)	Active and passive	Acute	CNS inflammation
	MOG	Active and passive	Chronic, relapsing-remitting	CNS inflammation and demyelination
	BTN (Butyrophilin) (aa 74–90)	Active	No disease	CNS inflammation
Brown Norway (BN)	MBP	Passive	Acute	CNS inflammation
(RT1-n)	Rat spinal cord	Active	Acute	CNS inflammation
	MOG	Active	Chronic progressive	CNS inflammation, demyelination
PVG (RT1-c)	MBP	Active resistant, passive susceptible	Acute	CNS inflammation
NON-HUMAN-PRIMATE-EAE
Macaca mulatta (Rhesus monkey)	Rabbit brain extract	Active	Acute and chronic progressive	CNS inflammation and demyelination
(Mamu-DPB1*01)
	Brain extract with adjuvant	Active	Acute and chronic	CNS inflammation with necrosis
	MOG (aa 4–20, 35–50, 94–116)	Active	Acute and chronic	CNS inflammation with necrosis
	MBP (aa 61–82, 80–105, 170–186)	Active and passive	Acute and chronic	CNS inflammation with necrosis
Macaca fascicularis (Cynomolgus monkey)	Brain homogenate	Active	Acute and CREAE	CNS inflammation, necrotic lesions
	MBP	Active	Acute and CREA	CNS inflammation, necrotic lesions
Macaca nemestrina	Brain homogenate and MBP	Active	Relatively resistant
Common marmoset (Calithrix jacchus)	Myelin homogenate	Active	Acute – chronic progressive	CNS inflammation, demyelination, necrotic lesions
Caja-DRB*W1201	MBP	Active and passive	Mild acute	CNS inflammation, no demyelination
	PLP	Active	Mild acute	CNS inflammation, no demyelination
	MOG (aa 1–124, 14–36)	Active	RR, secondary progressive	CNS inflammation and demyelination